In 2008 the ECASS III trial showed that IV r-tPA administered within three to 4.5 hours of stroke onset may offer a moderate benefit when applied to all patients with potentially disabling deficits.15 The incidence of intracranial haemorrhage was higher with IV r-tPA than with placebo in this study [27.0 vs 17.6% for any intracranial haemorrhage (p = 0.001) and 2.4 vs 0.2% for symptomatic intracranial hemorrhage (p = 0.008)], but mortality did not differ significantly between the two groups. The gene discussed is PLAT; the disease is stroke disorder.